Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $8.7 million.

  • Arcutis Biotherapeutics' Other Operating Expenses rose 5782.3% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 12055.43%. This contributed to the annual value of $19.1 million for FY2024, which is 28355.72% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Other Operating Expenses is $8.7 million, which was up 5782.3% from $7.5 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Other Operating Expenses high stood at $8.8 million for Q1 2025, and its period low was $269000.0 during Q3 2022.
  • In the last 4 years, Arcutis Biotherapeutics' Other Operating Expenses had a median value of $3.3 million in 2024 and averaged $3.8 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 36556.68% in 2024, then surged by 5782.3% in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Other Operating Expenses stood at $485000.0 in 2022, then surged by 363.09% to $2.2 million in 2023, then surged by 207.44% to $6.9 million in 2024, then increased by 25.78% to $8.7 million in 2025.
  • Its Other Operating Expenses stands at $8.7 million for Q3 2025, versus $7.5 million for Q2 2025 and $8.8 million for Q1 2025.